Work

CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells

Year: 2009

Type: article

Source: Leukemia

DOI: 10.1038/leu.2009.77

Authors: A Takeshita, N Yamakage, K Shinjo, T Ono, I Hirano, S Nakamura, K Shigeno, T Tobita, M Maekawa, H Kiyoi, T Naoe, K Ohnishi, Y Sugimoto, R Ohno

Institutions: Hamamatsu University, Hamamatsu University School of Medicine, Yaizu City Hospital, Nagoya University, Keio University, Aichi Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Wyeth Pharmaceuticals, RIKEN

OpenAlex ID: W1968488564

FWCI: 2.523

Cites: 26

Cited by: 34

Related to: 10